Akero Therapeutics’ (AKRO) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Akero Therapeutics (NASDAQ:AKRO) in a research note released on Monday,Benzinga reports. The brokerage currently has a $50.00 price target on the stock. HC Wainwright also issued estimates for Akero Therapeutics’ FY2028 earnings at $1.66 EPS.

Akero Therapeutics Trading Down 4.4 %

Shares of NASDAQ:AKRO opened at $30.97 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 24.89. Akero Therapeutics has a 52-week low of $13.86 and a 52-week high of $37.00. The stock has a 50 day moving average price of $29.27 and a 200-day moving average price of $25.46.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). On average, equities research analysts forecast that Akero Therapeutics will post -3.82 EPS for the current year.

Insider Transactions at Akero Therapeutics

In related news, CEO Andrew Cheng sold 1,738 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $26.18, for a total value of $45,500.84. Following the transaction, the chief executive officer now owns 605,417 shares in the company, valued at $15,849,817.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, COO Jonathan Young sold 50,716 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $31.57, for a total transaction of $1,601,104.12. Following the transaction, the chief operating officer now directly owns 216,286 shares of the company’s stock, valued at $6,828,149.02. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Andrew Cheng sold 1,738 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $26.18, for a total value of $45,500.84. Following the sale, the chief executive officer now directly owns 605,417 shares in the company, valued at $15,849,817.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 428,397 shares of company stock valued at $12,997,971 in the last ninety days. 7.94% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its stake in Akero Therapeutics by 2,366.0% during the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after buying an additional 1,183 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Akero Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after acquiring an additional 446 shares during the period. Eastern Bank bought a new position in Akero Therapeutics in the 3rd quarter worth $100,000. Headlands Technologies LLC grew its holdings in Akero Therapeutics by 253.5% during the first quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after purchasing an additional 3,024 shares during the period. Finally, Ameritas Investment Partners Inc. increased its position in Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after buying an additional 1,030 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.